PYC Therapeutics Advances Two RNA-Based Therapies for Inherited Blindness Conditions
核心洞察
PYC Therapeutics (搜索) received FDA regulatory alignment for a pivotal trial of VP 001, potentially the first approved treatment for Retinitis Pigmentosa type 11 (搜索), with a 36-month study targeting 15-letter visual acuity improvement.
The company's Safety Review Committee cleared PYC-001 for multiple-dose testing at 60 micrograms for Autosomal Dominant Optic Atrophy (搜索), advancing from single-dose Phase 1 evaluation.
Both RNA-based therapies target genetic causes of progressive vision loss in rare diseases affecting approximately one in 35,000 people, with no current approved treatments available.
PYC Therapeutics (搜索) has achieved significant regulatory and clinical milestones for two investigational RNA-based therapies targeting inherited blindness conditions, positioning the Perth and San Francisco-based biotechnology company to advance treatments for rare genetic eye diseases that currently have no approved therapeutic options.
FDA Clears Path for Pivotal RP11 Trial
The company announced regulatory alignment with the United States Food and Drug Administration on the design of a registrational study for VP 001, an investigational therapy that "has the potential to become the first approved treatment option for patients with the blinding eye disease Retinitis Pigmentosa type 11 (搜索)."
The FDA meeting established the framework for a pivotal study designed to measure whether VP 001 can improve vision in patients with RP11. The trial will evaluate the mean change from baseline in low-luminance visual acuity after 36 months of treatment, targeting a 15-letter improvement compared with the sham-treated group.
Secondary measures will assess both improvement and protection against further vision loss, including the proportion of patients achieving a ten-letter improvement in visual acuity and the proportion who avoid losing ten letters over the same period. Additional outcomes will monitor retinal sensitivity and the rate of structural changes in photoreceptors (搜索) over time.
Notably, regulators indicated that study success would not depend solely on reaching the primary 15-letter threshold. The FDA confirmed that failure to meet this benchmark would not necessarily prevent approval if broader results supported the therapy's safety and effectiveness, with the final decision depending on the "totality of evidence" once the trial is complete.
Safety Committee Advances Optic Atrophy Program
Simultaneously, PYC announced progress in the clinical development of PYC-001, its investigational therapy for Autosomal Dominant Optic Atrophy (搜索). An independent Safety Review Committee completed its assessment of early-stage trial data and cleared the way for the next phase of testing.
After reviewing four-week safety and tolerability outcomes in patients who received a 60 microgram dose, the committee approved advancing this dose to a multiple-dose study. This marks a key transition from initial safety evaluation toward broader clinical investigation, building on an ongoing Phase 1 program that initially explored single ascending doses.
PYC will now expand its work to include repeated dosing at 60 micrograms, alongside existing cohorts receiving 10 and 30 micrograms. The company is positioning this stage as a step toward establishing clinical proof of concept, with safety and efficacy results expected to be released progressively across 2026 and 2027.
Addressing Unmet Medical Needs
Autosomal Dominant Optic Atrophy (搜索) affects approximately one in 35,000 people and is caused by genetic mutations that impair the function of retinal cells (搜索). The condition leads to progressive vision loss and currently has no approved treatment options.
By targeting these diseases at a molecular level, PYC's approach aligns with precision medicine efforts to develop RNA-based therapies for conditions that have historically lacked viable treatment options. The company describes itself as a precision medicine developer focused on genetic diseases with no effective treatments, advancing additional RNA-based therapies targeting the underlying causes of inherited disorders.
PYC expects additional long-term clinical data from its ongoing Phase 2 study of VP 001 later this year, including results from patients who have received the therapy for more than twelve months, which will help determine next steps toward initiating the pivotal study.